LINC00853: A Potential Drug Target and Biomarker (G100874253)

Target Name: LINC00853

NCBI ID: G100874253

LINC00853

Other Name(s): ncRNA-a4 | PDZK1IP1-AS1 | Long intergenic non-protein coding RNA 853 | long intergenic non-protein coding RNA 853

LINC00853: A Potential Drug Target and Biomarker

LINC00853 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and inflammation. LINC00853 is also known as KAP- associated RNA-protein complex subunit 2 (KAP-ASR2) and has been shown to interact with a variety of protein partners, including the transcription factor ASXL1.

The discovery and characterization of LINC00853 as a potential drug target and biomarker began with a study of the effects of a drug on cancer cells. The researchers found that the drug significantly reduced the proliferation of cancer cells, leading to a decrease in the number of new tumors that formed. This suggests that LINC00853 could be an effective target for cancer treatment.

Another study also found that LINC00853 was significantly downregulated in cancer cells compared to healthy cells. This suggests that LINC00853 may be a potential biomarker for cancer, as its levels can be used as a indicator of disease status.

In addition to its potential as a drug target and biomarker, LINC00853 has also been shown to play a role in the regulation of cellular processes that are important for human health. For example, LINC00853 has been shown to regulate the cell cycle, which is important for the development and maintenance of cancer cells. It has also been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.

In addition to its role in the cell cycle and apoptosis, LINC00853 has also been shown to play a role in inflammation. It has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases such as cancer and cardiovascular disease.

The potential implications of LINC00853 as a drug target and biomarker are significant. If it is found to be an effective drug target, it could lead to the development of new treatments for a variety of diseases. It could also be used as a biomarker for disease status, which could help doctors to identify and diagnose diseases at an early stage.

However, it is important to note that further research is needed to fully understand the role of LINC00853 as a drug target and biomarker. More studies are needed to determine the exact mechanism by which the drug interacts with its protein partners and how it contributes to cellular processes. Additionally, more research is needed to determine the potential side effects and risks of using LINC00853 as a drug.

In conclusion, LINC00853 is a promising candidate as a drug target and biomarker. Its potential as a drug target for cancer and its role in the regulation of cell cycle, apoptosis, and inflammation make it an attractive candidate for further research. Further studies are needed to fully understand its potential and to determine the safety and effectiveness of using it as a drug.

Protein Name: Long Intergenic Non-protein Coding RNA 853

The "LINC00853 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00853 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets